EntryPoint Capital LLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• EntryPoint Capital LLC acquired 40,528 shares of BioCryst Pharmaceuticals valued at approximately $304,000, contributing to a strong interest from institutional investors as they own 85.88% of the stock.
• Analysts have positively adjusted their target prices for BioCryst Pharmaceuticals, with estimates ranging from $11.00 to $18.00, indicating strong market confidence in the company.
• BioCryst reported a significant revenue increase of 49.5% in the last quarter, with an earnings per share of $0.15 that surpassed analysts' expectations.

EntryPoint Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 40,528 shares of the biotechnology company's stock, valued at approximately $304,000.

Several other institutional investors and hedge funds have also modified their holdings of BCRX. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $32,000. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $33,000. GAMMA Investing LLC increased its position in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter worth about $62,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $79,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BCRX has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Wedbush raised their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. Finally, Barclays increased their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Stock Down 0.6%

Shares of BCRX stock traded down $0.05 during trading hours on Thursday, reaching $8.47. 562,052 shares of the company's stock were exchanged, compared to its average volume of 3,738,518. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $11.31. The stock has a market capitalization of $1.78 billion, a P/E ratio of -47.19, a P/E/G ratio of 1.95 and a beta of 1.10. The business has a fifty day moving average price of $8.73 and a 200-day moving average price of $8.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. During the same period last year, the firm posted ($0.06) EPS. The company's revenue was up 49.5% compared to the same quarter last year. As a group, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director directly owned 65,352 shares in the company, valued at $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.10% of the stock is currently owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.